Company Quick10K Filing
Immunocellular Therapeutics
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 42 $10
10-Q 2018-08-13 Quarter: 2018-06-30
10-Q 2018-05-14 Quarter: 2018-03-31
10-K 2018-03-14 Annual: 2017-12-31
10-Q 2017-11-21 Quarter: 2017-09-30
10-Q 2017-08-14 Quarter: 2017-06-30
10-Q 2017-05-15 Quarter: 2017-03-31
10-K 2017-03-09 Annual: 2016-12-31
10-Q 2016-11-10 Quarter: 2016-09-30
10-Q 2016-08-22 Quarter: 2016-06-30
10-Q 2016-05-13 Quarter: 2016-03-31
10-K 2016-03-30 Annual: 2015-12-31
10-Q 2015-11-09 Quarter: 2015-09-30
10-Q 2015-08-07 Quarter: 2015-06-30
10-Q 2015-05-11 Quarter: 2015-03-31
10-K 2015-03-10 Annual: 2014-12-31
10-Q 2014-11-10 Quarter: 2014-09-30
10-Q 2014-08-08 Quarter: 2014-06-30
10-Q 2014-05-09 Quarter: 2014-03-31
10-K 2014-03-14 Annual: 2013-12-31
10-Q 2013-11-07 Quarter: 2013-09-30
10-Q 2013-08-08 Quarter: 2013-06-30
10-Q 2013-05-10 Quarter: 2013-03-31
10-K 2013-03-11 Annual: 2012-12-31
10-Q 2012-08-14 Quarter: 2012-06-30
10-Q 2012-05-11 Quarter: 2012-03-31
10-K 2012-03-21 Annual: 2011-12-31
10-Q 2011-11-14 Quarter: 2011-09-30
10-Q 2011-08-18 Quarter: 2011-06-30
10-Q 2011-05-16 Quarter: 2011-03-31
10-K 2011-03-31 Annual: 2010-12-31
10-Q 2010-11-15 Quarter: 2010-09-30
10-Q 2010-08-16 Quarter: 2010-06-30
10-Q 2010-05-18 Quarter: 2010-03-31
10-K 2010-03-31 Annual: 2009-12-31
8-K 2018-10-16 Exhibits
8-K 2018-10-10 Officers, Exhibits
8-K 2018-08-13 Earnings, Exhibits
8-K 2018-05-14 Earnings, Exhibits
8-K 2018-03-13 Earnings, Exhibits
8-K 2018-02-13 Earnings, Exhibits
8-K 2018-01-29 Officers

Immunocellular Therapeutics Financials

IMUC Metrics, Comps, Filings

Annual | Quarterly

Business

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of cancers. Immunotherapy is an emerging approach to treating cancer in which a patient's own immune system is stimulated to target tumor antigens, which the immune system uses to identify foreign bodies. While some other cancer immunotherapies target only a single cancer antigen, our technology can elicit an immune response against several antigens simultaneously. Our clinical stage cancer immunotherapy programs are also distinguished by the fact that they target cancer stem cells (CSCs), which are the primary drivers of tumor growth and disease recurrence.

Review of Strategic Alternatives

We expect to devote substantial time and resources to exploring strategic alternatives that our board of directors believes will maximize stockholder value. Our consideration of strategic alternatives includes, but is not limited to, the potential for an acquisition, merger, business combination, licensing and/or other strategic transaction involving the company. Despite devoting significant efforts to identify and evaluate potential strategic transactions, we may not be successful in completing a transaction. Further, even if a strategic transaction is completed, it ultimately may not deliver the anticipated benefits or enhance stockholder value.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Sino Agro Food (SIAF) 10,995 17% 0.9 2% 791,662 79,087 105,291 18,169 16,660 17,404 15,837
New Bancorp (NWBB) 10,731 -1.6 0% 117,804 101,893 0 0 398 1,869 -3,046
Kiwa Bio-Tech (KWBT) 13,189 25% 175.6 -5% 33,145 19,558 31,454 7,926 -1,544 77 13,521
BioCorRx (BICX) 16,692 48% -2.2 -163% 4,497 4,483 229 109 -7,320 -5,906 13,102
Zenosense (ZENO) 10,638 -48.7 -112% 413 756 0 0 -464 -227 11,055
Applied Minerals (AMNL) 10,531 0% 94.4 -62% 1,359 44,589 438 0 -849 564 53,242
KinerjaPay (KPAY) 8,379 4% -0.5 -395% 4,308 9,409 361 14 -17,021 -16,996 8,254
Immunocellular Therapeutics (IMUC) 10,478 -1.3 -148% 3,829 402 0 0 -5,664 -5,664 7,626
Parks America (PRKA) 12,720 0% 5.1 10% 10,763 1,839 6,184 0 1,097 2,025 10,303
Sci Engineered Materials (SCIA) 10,457 18% 21.7 5% 7,754 3,758 10,012 1,849 384 404 8,763
International Baler (IBAL) 10,420 23% 22.2 1% 10,305 1,034 5,535 1,286 107 298 6,629
Duo World (DUUO) 11,575 62% -22.1 -52% 1,153 4,549 693 430 -601 -522 11,520
Sunstock (SSOK) 7,979 4% -0.6 -2,026% 643 10,583 3,930 170 -13,027 -12,827 7,954
Dais Analytic (DLYT) 0 36% 0.0 -597% 414 8,700 1,055 378 -2,470 -2,184 -14
AlphaPoint Technology (APPO) 10,360 0% -17.5 -853% 69 987 10 0 -590 -590 10,324
Nanoflex Power (OPVS) 11,453 0% -2.6 -1,984% 487 12,523 178 0 -9,654 -4,455 11,403
Global Healthcare REIT (GBCS) 10,153 0% 27.0 0% 40,263 38,873 4,879 0 180 1,775 47,949
Home Treasure Finders (HMTF) 10,377 0% 1,941.6 -8% 889 1,010 451 0 -73 5 10,281
SPYR (SPYR) 12,003 0% -11.9 -323% 380 4,091 104 0 -1,226 -1,003 11,967
Sunwin Stevia (SUWN) 9,982 14% -3.0 -9% 31,318 27,810 21,635 3,002 -2,804 -3,215 9,671

Balance Sheet ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-31
Cash6,65326,21727,64623,22222,60411,4376,630
Accounts Receivable
Inventory
PP&E7676185471811101
Assets7,15127,01928,94125,17930,08216,8907,009
Accounts Payable1,3177338613221,1611,3421,775
Long-Term Debt4,1346,9460
Liabilities3,9193,9512,4671,8878,36210,7582,361
Stockholders' Equity3,23223,06826,47423,29221,7206,1324,648
Income Statement ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-31
Revenue000000
Cost of Revenue
Gross Profit
R&D4,9897,7115,3405,96910,89719,10617,126
SG&A2,4473,6193,3963,2354,6165,0064,027
Tax000000
Net Income-5,720-14,495-8,801-9,378-12,791-22,086-14,312
Cash Flow ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-31
Cash Operating-6,384-12,380-8,787-9,937-19,039-19,864-16,672
Cash Investing-84-10-44-29-170-41
Cash Financing7,80231,95310,2615,54118,5918,70111,863